This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Merrimack Pharmaceuticals Inc (MACK)

NASDAQ: Health Care

Company Balance Sheet
Dec 2013 Dec 2012 Dec 2011 Dec 2010
Assets
Cash and Equivalents 65.09M 37.71M 50.45M 30.71M
Receivables 5.86M 9.27M 7.43M 3.74M
Inventories 0.00 0.00 0.00 0.00
Other Current Assets 0.00 0.00 0.00 0.00
Total Current Assets 166.64M 128.30M 65.59M 36.29M
Property, Plant & Equipment, Gross 34.91M 25.27M 22.34M 18.58M
Accumulated Depreciation & Depletion 21.55M 18.97M 16.13M 11.12M
Property, Plant & Equipment, Net 13.36M 6.30M 6.21M 7.46M
Intangibles 8.04M 9.18M 9.50M 9.82M
Other Non-Current Assets 759.00K 1.60M 404.00K 411.00K
Total Non-Current Assets 25.77M 20.67M 19.71M 21.29M
Liabilities & Shareholder Equity
Total Assets 192.42M 148.97M 85.30M 57.58M
Accounts Payable 1.89M 283.00K 4.66M 1.44M
Short Term Debt 8.25M 2.37M 48.00K 443.00K
Other Current Liabilities 1.36M 1.08M 0.00 0.00
Total Current Liabilities 57.73M 38.52M 26.15M 16.32M
Long Term Debt 103.43M 37.48M 0.00 0.00
Deferred Income Taxes 507.00K 755.00K 1.27M 810.00K
Other Non-Current Liabilities 73.88M 78.64M 79.57M 68.07M
Minority Interest 240.00K -477.00K -453.00K -55.00K
Total Non-Current Liabilities 178.15M 116.97M 349.64M 261.22M
Total Liabilities 235.88M 155.49M 375.79M 277.54M
Preferred Stock Equity 0.00 0.00 0.00 0.00
Common Stock Equity -43.46M -6.52M -290.49M -219.96M
Common Par 1.02M 958.00K 118.00K 111.00K
Additional Paid In Capital 527.78M 434.68M 60.23M 45.10M
Cumulative Translation Adjustment 0.00 0.00 0.00 0.00
Retained Earnings -572.24M -442.12M -350.84M -271.62M
Treasury Stock 0.00 0.00 0.00 0.00
Other Equity Adjustments -24.00K -38.00K 0.00 6.44M
Total Capitalization 59.96M 30.96M -290.49M -219.96M
Total Equity -43.46M -6.52M -290.49M -219.96M
Total Liabilities & Stock Equity 192.42M 148.97M 85.30M 57.58M
Total Common Shares Outstanding 102.52M 95.82M 92.40M 92.40M
Preferred Shares 0.00 0.00 0.00 0.00
Treasury Shares 0.00 0.00 0.00 0.00
Basic Weighted Shares Outstanding 98.92M 72.83M 11.34M 0.00
Diluted Weighted Shares Outstanding 98.92M 72.83M 11.34M 0.00
Number of Employees 254 230 218 NA
Number of Part-Time Employees 0 0 0 NA
MACK News

MACK Merrimack Pharmaceuticals Inc

Analysts Ratings for MACK

Rating Current 1-Mo Ago 2-Mo Ago 3-Mo Ago
Strong Buy 2 1 3 3
Moderate Buy 0 0 0 0
Hold 0 1 1 1
Moderate Sell 0 0 0 0
Strong Sell 0 0 0 0
GET MACK ANALYST REPORT

Brokerage Partners

MACK Chatter

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
Real Money Pro

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Trifecta Stocks

Trifecta Stocks analyzes over 4,000 equities weekly to find the elite 1% of stocks that pass rigorous quantitative, fundamental and technical tests.

Product Features:
  • Model portfolio
  • Trade alerts
  • Recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
Stocks Under $10

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Dividend Stock Advisor

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Breakout Stocks

Bryan Ashenberg, using sophisticated stock screening and fundamental research, identifies potentially explosive small and mid-cap stocks.

Product Features:
  • Model portfolio
  • Small-cap and mid-cap focus
  • Intraday trade alerts
  • Weekly roundups
Options Profits

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
Top Rated Stocks Top Rated Funds Top Rated ETFs